Enliven Therapeutics names Richard Fair CEO; co-founder Sam Kintz becomes Head of Pipeline

Enliven Therapeutics, Inc.

Richard Fair appointed President, CEO and board member, effective December 11, 2025.
Co-founder Sam Kintz transitions to Head of Pipeline, remains at Enliven.
Fair receives $660,000 base salary, 55% target bonus, and option award for 875,000 shares.
Kintz receives $500,000 base salary, 55% bonus, and acceleration of 140,457 stock options.
Company plans to initiate Phase 3 trial for ELVN-001 in CML in 2026, citing need for commercialization expertise.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.